• Skip to main content

Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

  • How To Publish
  • How to Write Plain Language Summaries
  • Frequently Asked Questions
  • Publications
    • Animated Videos
    • Bladder, Kidney and Genitals
    • Brain and Nerves
    • Cancer
    • Heart and Circulation
    • Infections
    • Muscle and Bone
    • Rare Diseases
    • Skin
    • Vaccines
  • Advisory Panel
  • Supporters
  • Blog
  • About Us
  • Contact Us

Bladder, Kidney and Genitals


  • Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial

    Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial

    Summary and patients perspectives of the ARASENS trial looking at treatment with darolutamide compared to placebo in combination with docetaxel and androgen-deprivation therapy for metastatic hormone-sensitive prostate cancer.

  • Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer

    Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer

    This is plain language summary provides an overview of the HERO study looking at how well relugolix works, compared with leuprolide, in men with advanced prostate cancer.

  • Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial

    Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial

    The latest plain language summary of publication (PLSP) published in Future Oncology provides a summary of the ARAMIS trial.

Copyright © 2022 · Plain Language Summaries · Terms and Conditions · Privacy Policy ·